Systematic review of health state utility values in metastatic non-small cell lung cancer with a focus on previously treated patients

被引：0
|
作者：
Noman Paracha
Ahmed Abdulla
Katherine S. MacGilchrist
机构：
[1] F. Hoffmann-La Roche AG,
[2] Epidemica Ltd,undefined
[3] Present address: Digipharm,undefined
来源：
Health and Quality of Life Outcomes | / 16卷
关键词：
Health state utility values (HSUVs); Health-related quality of life (HRQoL); Metastatic non-small cell lung cancer (mNSCLC); Multi-attribute utility instruments (MAUIs); Standard gamble (SG); Time trade-off (TTO); Systematic literature review;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Systematic review of health state utility values in metastatic non-small cell lung cancer with a focus on previously treated patients
    Paracha, Noman
    Abdulla, Ahmed
    MacGilchrist, Katherine S.
    [J]. HEALTH AND QUALITY OF LIFE OUTCOMES, 2018, 16
  • [2] HEALTH STATE UTILITY VALUES IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS
    Chevalier, J.
    Le Lay, K.
    de Pouvourville, G.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A419 - A419
  • [3] Health State Utility Values in Early-Stage Non-small Cell Lung Cancer: A Systematic Literature Review
    Nick Jovanoski
    Seye Abogunrin
    Danilo Di Maio
    Rossela Belleli
    Pollyanna Hudson
    Sneha Bhadti
    Libby G. Jones
    [J]. PharmacoEconomics - Open, 2023, 7 : 723 - 738
  • [4] Health State Utility Values in Early-Stage Non-small Cell Lung Cancer: A Systematic Literature Review
    Jovanoski, Nick
    Abogunrin, Seye
    Di Maio, Danilo
    Belleli, Rossela
    Hudson, Pollyanna
    Bhadti, Sneha
    Jones, Libby G.
    [J]. PHARMACOECONOMICS-OPEN, 2023, 7 (05) : 723 - 738
  • [5] Atezolizumab: A Review in Previously Treated Advanced Non-Small Cell Lung Cancer
    Blair, Hannah A.
    [J]. TARGETED ONCOLOGY, 2018, 13 (03) : 399 - 407
  • [6] Atezolizumab: A Review in Previously Treated Advanced Non-Small Cell Lung Cancer
    Hannah A. Blair
    [J]. Targeted Oncology, 2018, 13 : 399 - 407
  • [7] SYSTEMATIC LITERATURE REVIEW (SLR) OF HEALTH STATE UTILITY VALUES (HSUV) IN EPIDERMAL GROWTH FACTOR RECEPTOR MUTANT (EGFR-MUTANT) NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS PREVIOUSLY TREATED WITH TARGETED THERAPIES
    Shor, A.
    Forsythe, A.
    Li, S.
    Galaznik, A.
    [J]. VALUE IN HEALTH, 2018, 21 : S35 - S36
  • [8] Health state utility scores in advanced non-small cell lung cancer
    Doyle, Scott
    Lloyd, Andrew
    Walker, Mel
    [J]. LUNG CANCER, 2008, 62 (03) : 374 - 380
  • [9] Targeted Therapy in Patients With Non-small Cell Lung Cancer Previously Treated With Chemotherapy
    Drobniene, Monika
    Ciceniene, Audrone
    Zelviene, Terese Pipiriene
    Grigiene, Ruta
    Lachej, Nadezda
    Steponaviciene, Laura
    Aleknavicius, Eduardas
    [J]. MEDICINA-LITHUANIA, 2011, 47 (09): : 520 - 525
  • [10] Optimizing therapy in previously treated non-small cell lung cancer
    Miller, VA
    [J]. SEMINARS IN ONCOLOGY, 2006, 33 (01) : S25 - S31
12345